JENSEN FLEMMING STEEN 4

What Happened
Flemming Steen Jensen, EVP & Product Supply and Quality at Ascendis Pharma (ASND), sold 19,460 shares in an open-market sale on May 11, 2026. The shares were sold at $238.49 each for total proceeds of $4,641,021. This was a disposition (sale), which is generally considered routine insider selling rather than a bullish signal.

Key Details

• Transaction date: 2026-05-11 (reported on Form 4 filed 2026-05-12)
• Type: Open-market sale (Code S)
• Shares sold: 19,460 at $238.49 per share
• Total value: $4,641,021
• Shares owned after transaction: Not specified in the filing
• Notable footnotes: Filing lists insider role as "EVP & Product Supply and Quality"; no 10b5-1 plan, tax withholding, or other special instructions disclosed in the Form 4
• Timeliness: Filed one day after the transaction (appears timely under SEC Form 4 rules)

Context
Sales by executives can be routine (diversification, liquidity, tax planning) and do not, by themselves, indicate the insider's view of the company. Because this is a straight open-market sale and no additional context (e.g., 10b5‑1 plan) is provided, retail investors should treat it as a disclosure of a significant insider sale but not as a directional endorsement or rejection of Ascendis Pharma's prospects.